SBM 06
Alternative Names: SBM-06Latest Information Update: 23 Jan 2026
At a glance
- Originator Shilpa Biologicals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Colorectal cancer; Hodgkin's disease; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
Most Recent Events
- 07 Jan 2026 SBM 06 is available for licensing as of 07 Jan 2026. https://shilpabio.com/partnerships/
- 07 Jan 2026 Early research in Colorectal cancer in India (Parenteral), prior to January 2026 (Shilpa Biologicals pipeline, January 2026)
- 07 Jan 2026 Early research in Hodgkin's disease in India (Parenteral), prior to January 2026 (Shilpa Biologicals pipeline, January 2026)